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ABSTRACT 
Background 
The extent of influence of body mass index (BMIZ) and age on C-peptide at the diagnosis of 
type 1 diabetes is unknown. 
Objective 
We studied the influence of BMIZ and age on C-peptide measures at and soon after the diagnosis 
of type 1 diabetes (T1D). 
Subjects 
Data from Diabetes Prevention Trial-Type 1 (DPT-1) participants <18.0 years at diagnosis was 
analyzed. 
Methods 
Analyses examined associations of C-peptide measures with BMIZ and age in 2 cohorts: oral 
glucose tolerance tests (OGTT) at diagnosis (n=99); mixed-meal tolerance tests (MMTT) <6 
months after diagnosis (n=80). Multivariable linear regression was utilized. 
Results 
Fasting and area under the curve (AUC) C-peptide from OGTTs (n=99) at diagnosis and 
MMTTs (n=80) after diagnosis were positively associated with BMIZ and age (p<0.001 for all). 
Associations persisted when BMIZ and age were included as independent variables in regression 
models (p<0.001 for all). BMIZ and age explained 31%-47% of the variance of C-peptide 
measures. In an example, two individuals with identical AUC C-peptide values had an 
approximate 5-fold difference in values after adjustments for BMIZ and age. The association 
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between fasting glucose and C-peptide decreased markedly when fasting C-peptide values were 
adjusted (r=0.30, p<0.01 to r=0.07, n.s.).  
Conclusions 
C-peptide measures are strongly and independently related to BMIZ and age at and soon after the 
diagnosis of T1D. Adjustments for BMIZ and age cause substantial changes in C-peptide values, 
and impact the association between glycemia and C-peptide. Such adjustments can improve 
assessments of β-cell impairment at diagnosis.  
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INTRODUCTION 
C-peptide indices are utilized to assess the loss of insulin secretion prior to and after the 
diagnosis of type 1 diabetes (T1D) in both clinical and research contexts. Clinically, these 
measures are used to differentiate T1D from type 2 diabetes and in guiding therapy. In addition, 
particularly in the United States, insurers have used C-peptide thresholds for determining 
whether insulin pumps and sensors should be covered. In the research setting, C-peptide 
measures are used to examine patterns of insulin loss in natural history studies (1), and as entry 
criteria and endpoints in clinical trials assessing interventions intended to prevent insulin loss (2-
7).  
In examining β-cell function for these purposes, it is essential to minimize other factors that 
could influence C-peptide levels apart from the pathology that is specific to T1D. Such factors 
include adiposity and age. Adiposity is known to be associated with insulin resistance (8,9). 
Although the direct influence of age on insulin resistance is less certain (10), age could influence 
insulin secretion by other mechanisms, such as possibly influencing β-cell mass (11). Thus, it is 
important to characterize the associations of C-peptide measures with indicators of adiposity 
such as BMI and age at the diagnosis of T1D to avoid a misinterpretation of β-cell function.  
Since there is little information available regarding associations of C-peptide with BMI and age 
at the diagnosis of T1D, we have utilized Diabetes Prevention Trial-Type 1 (DPT-1) data to 
study the influence of BMI and age on C-peptide at the time of and soon after the diagnosis of 
T1D. In the DPT-1 study, a number of individuals were diagnosed by oral glucose tolerance 
testing which included C-peptide determinations. The findings presented below provide 
information that is relevant to assessments of β-cell function in both clinical and research 
settings.  
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METHODS 
Subjects 
Subjects who participated in the parenteral (12) and oral (13) insulin DPT-1 trials have 
previously been described in detail. All of the participants had islet cell autoantibodies and all 
were related to patients with T1D; neither the parenteral nor the oral insulin interventions 
showed efficacy. All participants included in the analysis were <18.0 years of age at diagnosis. 
Two analyses were performed from that cohort: a 2-hour oral glucose tolerance test (OGTT) 
analysis at the time of diagnosis, and a 2-hour mixed meal tolerance test (MMTT) analysis in the 
post-diagnostic period. For the OGTT analysis, all included were required to have BMI (kg/m2) 
measurements on the same date as the diagnostic OGTTs. Ninety-nine had BMI measurements 
on that date. Of those analyzed at diagnosis with OGTTs, 62 were in the parenteral insulin trial 
(intervention: 36; controls: 26) and 37 were in the oral insulin trial (intervention: 18; controls: 
19). Criteria for inclusion in the MMTT analysis were the performance of MMTTs within 6 
months after diagnosis and a BMI measurement within ±6 months of the MMTT. Of the 80 
included in the MMTT analysis 52 were in the parenteral insulin trial (intervention:30; controls 
22) and 28 were in the oral insulin trial (intervention:11; controls: 17). The mean±SD interval 
from diagnosis to MMTTs was 0.24±0.10 years. Since each analysis had its own inclusion 
criteria, the participants could differ between the cohorts; overall, 53 individuals were included 
in both cohorts.  DPT-1 was approved by institutional review boards at all participating sites, and 
written informed consents or assents as appropriate were obtained. 
Procedures 
As previously described (12,13), in both the parenteral and oral insulin DPT-1 trials, OGTTs 
were originally performed at 6-month (±3 months) intervals for diagnostic surveillance. After an 
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oral glucose dose of 1.75 g per kilogram (maximum, 75 g of carbohydrate), fasting, 30, 60, 90 
and 120 minute samples were obtained for glucose and C-peptide measurements. All of those 
included in the analysis were diagnosed by American Diabetes Association criteria. When an 
OGTT was within the diabetic range (fasting glucose values ≥126 mg/dl and/or 2-hr glucose 
values ≥200 mg/dl), a second OGTT was to be performed within 60 days unless clinically 
contraindicated. If the second OGTT was confirmatory, the age at the first diabetic OGTT was 
considered the age at diagnosis. The first diabetic OGTT (i.e., the diagnostic OGTT) was used 
for the OGTT analysis. For the MMTTs, glucose and C-peptide measurements were obtained 
before and after the consumption of a liquid formula meal (Sustacal/Boost, Mead Johnson 
Nutritionals; 6 kcal/kg body weight, maximum 360 kcal). Insulin dosing was held the morning of 
the OGTT until after test completion. Since children were analyzed, BMI Z-scores (BMIZ) were 
used for all analyses of BMI. The BMIZ values reflect BMI measures adjusted for age and sex 
based on Centers for Disease Control reference values (2000 growth charts). BMIZ is used as an 
indicator of the degree of adiposity. 
Laboratory Measures 
Plasma glucose levels were measured by the glucose oxidase method. C-peptide levels were 
measured by radioimmunoassay.  Fasting C-peptide values in the undetectable range (<0.2 
ng/ml) were assigned a value of 0.1 ng/ml for the analyses. Three C-peptide measures were 
analyzed: fasting, area under the curve (AUC), and the 30-0 minute difference. The latter was 
included in the analysis, since it correlates with the first phase insulin response and declines 
during the latter stages of progression to T1D (14). The same C-peptide measures were used for 
the OGTT and MMTT analyses. 
 
8 
 
Data Analysis 
Each of the analysis cohorts (OGTT and MMTT) were characterized using summary statistics, 
and two-sample t-tests and chi-square tests were used to compare factors and measures between 
groups of interest. Univariate and multivariable generalized linear regression models were used 
to examine associations of C-peptide variables with BMIZ and age. Models for each of the 
analysis cohorts were evaluated that adjusted for BMIZ alone, age alone, and for both. Pearson 
correlations were also utilized. Exploratory analyses supported the use of untransformed C-
peptide measures; in addition, associations were similar when C-peptide values were log 
transformed.  
To illustrate and further evaluate the influence of BMIZ and age on AUC C-peptide, coefficients 
for BMIZ and age for each of these fitted models were used to calculate an adjusted AUC C-
peptide estimate from OGTTs at diagnosis and MMTTs after diagnosis. The influence of 
removing subject-specific BMIZ and age-related effects on AUC C-peptide was assessed by 
subtracting the subject-specific effects for BMIZ and age, according to the fitted models, from 
the actual observed AUC C-peptide value. We explored this delineation of effects added to the 
estimated AUC C-peptide that were specific to BMIZ and/or age for the individual difference 
from the average subject. In this context, those in the extremes for BMIZ or age in relation to the 
average cohort subject will have a greater adjustment to their AUC C-peptide than those whose 
BMIZ or age are near the overall average. An example of the formulaic approach for this 
functional adjustment is:  
𝑦?̃? = 𝑦𝑖 − (𝑦?̂? − 𝑦𝑎𝑣?̂?)  
𝑦?̃? = 𝑦𝑖 − (𝛽0̂ + 𝛽1̂𝐵𝑀𝐼𝑍𝑖 − (𝛽0̂ + 𝛽1̂𝐵𝑀𝐼𝑍̅̅ ̅̅ ̅̅ ̅̅ ))  
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 𝑦?̃? = 𝑦𝑖 − (𝛽0̂ + 𝛽1̂𝐵𝑀𝐼𝑍𝑖 − 𝛽0̂ − 𝛽1̂𝐵𝑀𝐼𝑍̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ) 
𝑦?̃? = 𝑦𝑖 − (𝛽0̂ − 𝛽0̂ + 𝛽1̂𝐵𝑀𝐼𝑍𝑖 − 𝛽1̂𝐵𝑀𝐼𝑍̅̅ ̅̅ ̅̅ ̅̅ ̅̅ )  
𝑦?̃? = 𝑦𝑖 − (𝛽1̂𝐵𝑀𝐼𝑍𝑖 − 𝛽1̂𝐵𝑀𝐼𝑍̅̅ ̅̅ ̅̅ ̅̅ ̅̅ )  
where 𝑦?̂? = 𝛽0̂ + 𝛽1̂𝐵𝑀𝐼𝑍𝑖 is the predicted model-based estimate of AUC C-peptide for a 
specific subject and their corresponding BMIZ, 𝑦𝑎𝑣?̂? = 𝛽0̂ + 𝛽1̂𝐵𝑀𝐼𝑍̅̅ ̅̅ ̅̅ ̅̅  is the predicted model-
based estimate of AUC C-peptide using the mean BMIZ from the overall analysis cohort, and yi 
is the actual observed AUC C-peptide for the specific subject of interest. Thus, if our regression 
coefficient for BMIZ is 0.459, we would calculate the functional component of AUC C-peptide 
adjusted for BMIZ as 𝑦𝑖 − 0.459𝑥(𝐵𝑀𝐼𝑍𝑖 − 𝐵𝑀𝐼𝑍̅̅ ̅̅ ̅̅ ̅̅ ̅̅ ). These adjustments were utilized to assess 
the influence of such a correction and the possible roles BMIZ and age have on AUC C-peptide 
at or soon after the diagnosis of T1D. The same methodology was used to assess the influence of 
BMIZ and age on the fasting C-peptide. Pearson correlations were used to assess the impact of 
associations between glucose and C-peptide variables. 
For the figure, data was categorized according to tertiles; comparisons were made between the 
highest and lowest groups. OGTT and MMTT AUCs were calculated with the trapezoidal rule. 
The SAS 9.2 version was used for the analyses. All p-values are two-sided with a significance 
level set at 0.05. 
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RESULTS 
There were 99 DPT-1 participants with OGTTs at diagnosis (mean±SD age at diagnosis: 
11.3±3.3 years; mean±SD BMIZ at diagnosis: 0.42±1.13; 58% male) who were analyzed. Also, 
80 DPT-1 participants were analyzed who had MMTTs within 6 months after diagnosis (age at 
MMTT: 11.8±3.4 years; BMIZ at MMTT: 0.52±1.08; 53% male). Characteristics of the 
participants are shown in Table 1, and values of C-peptide indices from the OGTTs and MMTTs 
are shown in Table 2. There were no differences between males and females for any of the C-
peptide measures. 
Regression coefficients for the associations of fasting C-peptide, 30-0 minute C-peptide 
difference, and AUC C-peptide from the OGTTs and MMTTs with BMIZ and age are shown in 
Table 3. There were substantial positive associations of the fasting and AUC C-peptide from the 
OGTTs with BMIZ and with age (p<0.001 for both). However, the 30-0 minute C-peptide 
difference was not significantly associated with BMIZ or with age.  
The associations of the fasting and AUC C-peptide from the MMTTs with BMIZ and with age 
were also positive and significant (p<0.001 for all). Their magnitudes were similar to those for 
the OGTT associations. However, in contrast to the OGTTs, there was also a significant 
association of the 30-0 minute C-peptide difference with BMIZ (p<0.05). There were no 
significant associations of any of the C-peptide measures from the OGTTs or the MMTTs with 
gender. 
Figure 1 shows C-peptide values for each OGTT time point according to BMIZ (A) and age (B) 
tertiles. The C-peptide values were significantly greater for the highest BMIZ tertile than for the 
lowest tertile at all OGTT time points (p<0.01 for all). The differences were even greater 
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between the highest and lowest age tertiles (p<0.001 at all of the OGTT time points). For BMIZ, 
the values of the middle tertile were slightly higher than the values of the lowest tertile, whereas 
for age the values of the middle tertile were closer to the highest tertile.  
Table 4 shows data from regression models with the C-peptide indices of the OGTTs and 
MMTTs as dependent variables, and BMIZ and age included together as independent variables 
for each model.  Fasting and AUC C-peptide levels were significantly related to BMIZ and age 
in each model for both OGTTs and MMTTs. The R2 (the proportion of the variance explained by 
BMIZ and age together in the models) for the associations of the fasting and AUC C-peptide 
with BMIZ and age varied from 0.31 to 0.47 for the OGTTs and MMTTs. Notable were the 
similarities of the multivariable coefficients in Table 4 to the univariate coefficients in Table 3. 
These findings indicate that the associations with BMIZ and age were largely independent of 
each other. 
To demonstrate the extent of influence of BMIZ and age on C-peptide levels at diagnosis, we 
adjusted AUC C-peptide values to mean BMIZ and mean age values of the 99 children in the 
OGTT cohort and the 80 children in the MMTT cohort (Table 5).  In the example shown, a 2.87 
ng/ml/120 AUC C-peptide value of a 5 year-old child at the 10th BMIZ percentile of the OGTT 
cohort (BMIZ value=-1.13) would increase to an adjusted AUC C-peptide value of 4.91 
ng/ml/120. Conversely, a 2.87 ng/ml/120 AUC C-peptide value in a 17 year-old adolescent at the 
90th BMIZ percentile would decrease to an adjusted AUC C-peptide value of 0.97 ng/ml/120.  
Thus, although the actual AUC C-peptide values were the same for each child, the adjusted AUC 
C-peptide value (i.e., after removal of the influence of BMIZ and age) was approximately 5-fold 
higher in the younger and thinner child. A large divergence was similarly evident for the adjusted 
AUC C-peptide from the MMTTs.  
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We examined the extent to which BMIZ and age influenced the impact of C-peptide on glycemia 
at diagnosis. Whereas there was a significant association of fasting glucose values (log 
transformed) with unadjusted fasting C-peptide levels (r=0.30, p<0.01), there was little 
association when fasting C-peptide levels were adjusted for BMIZ and age (r=-0.07, n.s.). There 
were significant associations of AUC glucose with both unadjusted and adjusted AUC-C-peptide 
levels; however, the association tended to be stronger (negatively) with adjusted AUC C-peptide 
levels (r=-0.37, p<0.001 for adjusted; r=-0.30, p<0.01 for unadjusted).  
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DISCUSSION 
The findings showed that at the diagnosis of T1D, an appreciable proportion of the variance of 
the fasting and AUC C-peptide from OGTTs was explained by BMIZ and age. Notably, the 
associations of the C-peptide indices with BMIZ and age were independent of each other in 
multivariable models. When the AUC C-peptide was adjusted for BMIZ and/or age, the C-
peptide values differed markedly from the actual values.  
There is an appreciable loss of C-peptide after diagnosis (15,16). Since MMTTs occurred on 
average about 3 months after the OGTTs, it appears that despite the loss of C-peptide after 
diagnosis, the magnitude of the association of C-peptide with BMIZ and age persists.  
The independence of BMIZ and age in their associations with the C-peptide indices suggests that 
the basis for the associations differs between BMIZ and age. Evidence from prior studies are 
consistent with this finding. Whereas studies have consistently shown associations between 
insulin resistance and indicators of the degree of adiposity such as BMI in other populations 
(8,9), the relationship of insulin resistance with age is less certain (10). Since some β-cell 
characteristics are associated with age (11,17), it is possible that insulin secretion might be better 
sustained in older individuals who develop T1D. Age has been shown to be a mitigating factor 
for the risk of T1D (18) and for the loss of C-peptide levels soon after diagnosis (16). 
The associations of C-peptide with BMIZ and age are clinically relevant, since C-peptide 
measurements are sometimes used to help differentiate the types of diabetes at diagnosis and to 
guide therapy. Also, low C-peptide values have been used as a criterion for providing insurance 
coverage of insulin pumps and glucose sensors. Thus, overweight and older children recently 
diagnosed with T1D could be less likely to obtain coverage than thinner and younger children.  
14 
 
These findings also have implications with regard to clinical trials evaluating interventions for 
preserving β-cell function in recently diagnosed T1D patients. Such trials have used the AUC C-
peptide from MMTTs as endpoints (2-7). Adjustments of the AUC C-peptide have been made 
for age in those trials, but not for the degree of BMI. Moreover, the findings are also relevant to 
the selection of subjects for trials, since C-peptide levels below a minimum threshold are used as 
an exclusion criterion. Without appropriate adjustments for BMI and age, younger and thinner 
children would more likely be excluded from clinical trials than overweight adolescents.  
Since adjustments of C-peptide for BMIZ and age essentially exclude the portion of C-peptide 
that is attributable to those characteristics, we examined differences between unadjusted and 
adjusted C-peptide values with regard to their associations with glucose values. The analysis 
showed that the positive association between the fasting glucose and fasting C-peptide was 
especially impacted by the adjustment, indicating that the association was almost fully 
attributable to BMIZ and age. The adjustment of the AUC C-peptide resulted in a stronger 
inverse association with the AUC glucose, but the impact was smaller. 
Despite the substantial impact of BMIZ and age on C-peptide values, adjustments might not 
always be warranted. For example, adjustments for age could obscure the reasonable possibility 
that β-cell compromise is less severe at the diagnosis of T1D in older individuals. Thus, for 
natural history studies of β-cell decline, age stratification might be more appropriate than age 
adjustment. As more is learned about the bases for the associations of C-peptide with BMIZ and 
age, decisions regarding the need for adjustment can be made with more certainty.  
The adjustments demonstrating the extent to which BMIZ and age influenced C-peptide levels 
do not necessarily generalize to other populations, since the coefficients for the associations 
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could differ among populations. However, similar modeling procedures for adjustments could be 
utilized. 
One of the limitations of the study was the lack of assessment of insulin resistance. We chose not 
to use indirect measures such as HOMA-IR, as they have not been validated in newly diagnosed 
T1D patients. In addition, since pubertal status was not ascertained at the time of diagnosis, we 
could not determine the extent of association between C-peptide indices and puberty. Insulin 
resistance has been shown to be associated with puberty (8). As a result of OGTT surveillance, it 
is likely that the diagnosis in DPT-1 occurred earlier than the typical diagnosis made clinically. 
Thus, the associations are not necessarily indicative of those at the time of a clinical diagnosis. 
Finally, since the analyses were cross-sectional, inferences could not be made on β-cell decline. 
No prior studies have examined the impact of BMIZ and age on C-peptide indices from OGTTs 
at diagnosis, including their impact on associations between glucose and C-peptide. Recent 
studies (19,20) found that random C-peptide levels at diagnosis were higher in children with a 
greater degree of adiposity, and in older children. In a DPT-1 analysis, a correlation was 
observed between the AUC C-peptide from MMTTs and age in individuals at risk for T1D (21). 
A study of children and adult T1D patients within 3 months of their diagnosis found positive 
associations of the AUC C-peptide from MMTTs with BMIZ and age (16).  
In conclusion, the findings indicate that BMIZ and age substantially and independently influence 
C-peptide levels at and soon after the diagnosis of T1D. These associations should be considered 
in both clinical and research settings. Although adjustments for BMIZ and age can add clarity to 
assessments of β-cell function, they should only be undertaken after determining their 
appropriateness for a particular objective. 
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Table 1. Characteristics of the OGTT and MMTT cohorts 
 OGTT Cohort (n=99) MMTT Cohort (n=80) 
Age at Baseline (years) 9.0±3.1 9.3±3.3 
Age at Diagnosis (years) 11.3±3.3 11.6±3.4 
Age at MMTTs (years) -------- 11.8±3.4 
Height (cm) 149.0±18.2 150.0±18.9 
HeightZ 0.55±0.99 0.33±0.84 
Weight (kg) 46.0±19.2 47.6±19.1 
WeightZ 0.61±1.04 0.55±0.99 
BMI (kg/m2) 19.8±4.5 20.2±4.5 
BMIZ 0.42±1.13 0.52±1.08 
HbA1c (%) 6.1±0.8 -------- 
Gender (% Male) 57.6 52.5 
mean±SD values shown except for Gender 
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Table 2. Mean±SD C-peptide values of OGTTs at diagnosis and MMTTs within 0.5 years after diagnosis 
 OGTT (n=99) MMTT (n=80) 
Fasting C-peptide (ng/ml) 1.34±0.89 1.02±0.63 
30-0 Minute C-peptide Difference (ng/ml) 1.31±1.01 1.45±1.19 
AUC C-peptide (ng/ml)/120 2.87±1.54 2.39±1.29 
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Table 3. Regression coefficients and R2 (in parentheses) for univariate associations of C-peptide 
indices with BMIZ and age for OGTTs at diagnosis and for MMTTs within 0.5 years after diagnosis  
OGTT (n=99) BMIZ Age (Years) 
Fasting C-peptide (ng/ml) 0.41±0.07 (0.27)++ 0.13±0.02 (0.23)++ 
30-0 Minute C-peptide Difference (ng/ml) 0.07±0.09 (0.01) 0.05±0.03 (0.03) 
AUC C-peptide (ng/ml)/120 min 0.46±0.13 (0.11)++ 0.23±0.04 (0.24)++ 
MMTT (n=80)   
Fasting C-peptide (ng/ml) 0.25±0.06 (0.19)++ 0.07±0.02 (0.15)++ 
30-0 Minute C-peptide Difference (ng/ml) 0.31±0.12 (0.08)+ 0.04±0.04 (0.02) 
AUC C-peptide (ng/ml)/120 min 0.44±0.13 (0.13)++ 0.15±0.04 (0.16)++ 
+p<0.05; ++p<0.001 
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Table 4. Regression coefficients from models that included C-peptide indices as dependent variables with BMIZ 
and age as independent variables for OGTTs at diagnosis and for MMTTs within 0.5 years after diagnosis 
 OGTT (n=99)  MMTT (n=80) 
 BMIZ Age (Years)  R2  BMIZ Age (Years) R2 
Fasting C-peptide (ng/ml) 0.38±0.06++ 0.12±0.02++ 0.47  0.27±0.05++ 0.07±0.02++ 0.36 
30-0 Minute C-peptide Difference 
(ng/ml) 
0.06±0.09 0.05±0.03 0.03  0.31±0.12+ 0.05±0.04 0.10 
AUC C-peptide (ng/ml)/120 min  0.42±0.11++ 0.22±0.04++ 0.33  0.46±0.11++ 0.16±0.04++ 0.31 
+p<0.05; ++p<0.001 
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Table 5. Examples of AUC C-peptide values adjusted for BMIZ, age, or both from regression coefficients 
for 2 individuals at opposite ends of BMIZ and age distributions with same AUC C-peptide at diagnosis   
 
AUC C-peptide=2.87 from OGTT 
at Diagnosis 
 
AUC C-peptide=2.39 from MMTT 
after Diagnosis 
Adjusted 
for BMIZ 
Adjusted 
for Age   
Adjusted 
for Both 
 
Adjusted 
for BMIZ 
Adjusted 
for Age  
Adjusted 
for Both 
Age=5 Years; BMIZ=10th %tile 3.58 4.32 4.91  2.98 3.43 4.10 
Age=17 Years; BMIZ=90th %tile 2.17 1.56 0.97  1.76 1.60 0.90 
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Figure 1 
Shown are mean AUC C-peptide levels during OGTTs according to BMIZ and age tertiles. 
Those in the highest tertiles of BMIZ and age had markedly higher AUC C-peptide levels than 
those in the lowest tertiles. For BMIZ, the values of the middle tertile were slightly higher than 
the values of the lowest tertile, whereas for age the values of the middle tertile were closer to the 
highest tertile. The ages of those in the middle BMIZ tertile (10.6±3.2 years) tended to be lower 
than the ages of those in the lowest 11.4±3.6 and highest 11.8±3.1 tertiles. After an adjustment 
for age, the AUC C-peptide values of the middle BMIZ tertile moved further from the lowest 
tertile (from 13% of the difference between the highest and lowest tertiles to 28% of the 
distance).   
 
